FI59796C - Foerfarande foer framstaellning av antiulceroesa 5-fenoxi-4-aminopyrimidiner - Google Patents

Foerfarande foer framstaellning av antiulceroesa 5-fenoxi-4-aminopyrimidiner Download PDF

Info

Publication number
FI59796C
FI59796C FI2796/73A FI279673A FI59796C FI 59796 C FI59796 C FI 59796C FI 2796/73 A FI2796/73 A FI 2796/73A FI 279673 A FI279673 A FI 279673A FI 59796 C FI59796 C FI 59796C
Authority
FI
Finland
Prior art keywords
phenoxy
solution
phenoxypyrimidine
preparation
hours
Prior art date
Application number
FI2796/73A
Other languages
English (en)
Finnish (fi)
Other versions
FI59796B (fi
Inventor
Christopher Andrew Lipinski
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of FI59796B publication Critical patent/FI59796B/fi
Publication of FI59796C publication Critical patent/FI59796C/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60Three or more oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI2796/73A 1972-09-08 1973-09-07 Foerfarande foer framstaellning av antiulceroesa 5-fenoxi-4-aminopyrimidiner FI59796C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US287423A US3862190A (en) 1972-09-08 1972-09-08 5-(unsubstituted and substituted phenoxy)-4-amino pyrimidines
US28742372 1972-09-08

Publications (2)

Publication Number Publication Date
FI59796B FI59796B (fi) 1981-06-30
FI59796C true FI59796C (fi) 1981-10-12

Family

ID=23102839

Family Applications (1)

Application Number Title Priority Date Filing Date
FI2796/73A FI59796C (fi) 1972-09-08 1973-09-07 Foerfarande foer framstaellning av antiulceroesa 5-fenoxi-4-aminopyrimidiner

Country Status (13)

Country Link
US (1) US3862190A (xx)
JP (1) JPS5543463B2 (xx)
AR (1) AR202106A1 (xx)
AU (1) AU471279B2 (xx)
BE (1) BE804414A (xx)
CA (1) CA996116A (xx)
CH (1) CH581121A5 (xx)
DE (1) DE2344611A1 (xx)
ES (1) ES418567A1 (xx)
FI (1) FI59796C (xx)
FR (1) FR2198753B1 (xx)
GB (1) GB1434805A (xx)
NL (1) NL7312270A (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941889A (en) * 1972-09-08 1976-03-02 Pfizer Inc. 5-(Substituted phenoxy)-4-amino pyrimidines as anti-ulcer agents
JPS57164686U (xx) * 1981-04-11 1982-10-16
JPS6197973U (xx) * 1984-12-03 1986-06-23
JPS63135868U (xx) * 1987-02-26 1988-09-06
WO1998014430A1 (fr) * 1996-10-02 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Derives de pyrimidine
US6440965B1 (en) * 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
US7205297B2 (en) * 2000-07-24 2007-04-17 Krenitsky Pharmaceuticals, Inc. Substituted 5-alkynyl pyrimidines having neurotrophic activity
WO2012086768A1 (ja) 2010-12-24 2012-06-28 日本農薬株式会社 ベンジルオキシピリミジン誘導体及び該誘導体を含有する農園芸用殺虫剤並びにその使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB886693A (en) * 1959-03-04 1962-01-10 Ici Ltd Heterocyclic compounds

Also Published As

Publication number Publication date
JPS4992080A (xx) 1974-09-03
AR202106A1 (es) 1975-05-15
CH581121A5 (xx) 1976-10-29
DE2344611A1 (de) 1974-03-14
AU471279B2 (en) 1976-04-15
AU6003173A (en) 1975-03-06
US3862190A (en) 1975-01-21
JPS5543463B2 (xx) 1980-11-06
FI59796B (fi) 1981-06-30
GB1434805A (en) 1976-05-05
ES418567A1 (es) 1976-08-01
FR2198753B1 (xx) 1976-09-03
FR2198753A1 (xx) 1974-04-05
CA996116A (en) 1976-08-31
NL7312270A (xx) 1974-03-12
BE804414A (fr) 1974-03-04

Similar Documents

Publication Publication Date Title
FI73433B (fi) Foerfarande foer framstaellning av farmakologiskt vaerdefulla imidazo/1,2-a/pyraziner.
SU1349700A3 (ru) Способ получени (2-оксо-1,2,3,5-тетрагидроимидазо-/2,1- @ /хиназолинил)оксиалкиламидов,их оптических изомеров или фармакологически приемлемых солей с кислотами
SU1375127A3 (ru) Способ получени производных 1,2-диаминоциклобутен-3,4-диона или их хлоргидратов
SU1240356A3 (ru) Способ получени производных тиазолидина
CZ281868B6 (cs) Bis-naftalimidy, způsob jejich výroby a farmaceut ické přípravky na jejich bázi
FI59796C (fi) Foerfarande foer framstaellning av antiulceroesa 5-fenoxi-4-aminopyrimidiner
US4968701A (en) 4-Quinoline carboxylic acid derivatives useful as immunosuppressive agents
EP0218027A1 (en) Novel guanidinomethylbenzoic acid derivatives
SU1574177A3 (ru) Способ получени производных 4,5-дигидрооксазолов
US4180588A (en) Immunosuppressant
US4939164A (en) Strontium salt
SU1657057A3 (ru) Способ получени имидазолпроизводных или их фармацевтически приемлемых солей с кислотами
EP0425283B1 (en) Novel triazolyl hydrazide derivatives and process for their preparation
EP0618901B1 (en) Highly water soluble bis-naphthalimides useful as anticancer agents
US4515806A (en) Furan derivatives and addition salts thereof pharmaceutical compositions and the therapeutical applications thereof
CA2204007A1 (en) Remedy for diseases caused by infection with helicobacter
FI68220B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbar n-(1-metyl-2-pyrrolidinylmetyl)-2,3-dimetoxi-5-metylsulfamoylbensamid
US3941889A (en) 5-(Substituted phenoxy)-4-amino pyrimidines as anti-ulcer agents
SK695188A3 (en) Enolether amide 1,1-dioxo-6-chloro-4-hydroxy-2-methyl-n-(2- -pyridyl)-2h-thieno (2,3-e)-1,2-thiazine-3-carboxylic acid, method of its production and pharmaceutical agent
SU791241A3 (ru) Способ получени производных 4,5,6,7-тетрагидроимидазо 4,5-с пиридина
JPH0114235B2 (xx)
SU1001855A3 (ru) Способ получени 2-замещенных-1н-фенантро[9,10- @ ]имидазолов или их солей
US3814766A (en) 11-deoxoglycyrrhetinic acid piperazides useful as antiulcer agents
US5489609A (en) 2-aminoethanesulfonic acid zinc complex compound
SU1217258A3 (ru) Способ получени производных 2-гуанидино-4-гетероарилтиазола или их фармацевтически приемлемых кислотно-аддитивных солей